Utility of aspirin in hospitalized COVID-19 patients
A recent paper published in Anesthesia & Analgesia Journal evaluated the possible benefits of using aspirin in hospitalized COVID-19 patients
Tag: Covid-19
Alpha-CD-containing oral spray to inhibit the SARS-CoV-2 endocytosis
Italian researchers developed an oral spray (Endovir Stop) containing alpha-cyclodextrin (0.2%) and hydroxytyrosol (3.8%) for the improvement of the defenses
FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Pfizer and BioNTech announced vaccine candidate against covid-19 achieved success in first interim analysis from Phase 3 study
Pfizer’s Early Data Shows Vaccine Is More Than 90% Effective Pfizer and BioNTech announced on 09 October their mRNA-based vaccine
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s
U.S. FDA Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is
Gilead debates WHO results on low effectivity of remdesivir in Covid-19 mortality rate
Pharmafile reports that Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections,
COVID-19 is Less Frequent at High Altitude Under Hypobaric conditions: The South-American Experience
As a cyclodextrin (SBECD) is used in one of the most potent drug formulation against Covid-19 the readers of the
Combined therapy (remdesivir, dexamethasone and monoclonal antibodies) for the treatment of President Trump
Science News reported on October 5, 2020 the opinion of Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital